Volpara confirms board changes aimed at driving US growth

Latest News

Volpara Health (ASX:VHT) has announced changes to its board of directors with the aim of enhancing its expertise on patient data and US healthcare networks.

The company is focused on health technology software that provides an integrated breast care platform for the delivery of personalised care.

Highly experienced senior healthcare general manager and finance executive Ann Custin will join the board as an independent, non-executive Director, effective 1 September 2021.

She brings a network of industry contacts from an extensive career in healthcare across Europe, the Americas, and Asia. Her most recent executive role was with Siemens Healthineers, where she served as both chief financial officer and board director of Siemens Medical Solutions. She previously served as chief operating and financial officer of Scient’x and President and CEO of USA Draeger Medical Systems.

Ms Custin is also a non-executive director of NASDAQ-listed Establishment Labs Holdings. It is a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, and has a market capitalisation of approximately US$1.7 billion.

Volpara has also announced that non-executive dDirector Dr Monica Saini has retired from its board of directors, effective 18 August 2021, as she focuses her efforts on direct patient care and health advocacy through her private breast cancer screening practice. 

Volpara chair Paul Reid said, “We welcome Ann Custin, an experienced healthcare executive and board director in the United States, to the Board of Volpara. We are also sad to see Monica leave the Board, to pursue her own direct agenda to help save women’s lives, but we thank her for her valuable contribution to the Board and the Company."